Tech Center 1600 • Art Units: 1632
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19361182 | METHODS AND COMPOSITIONS FOR PRODUCING GRANULOSA-LIKE CELLS | Non-Final OA | President and Fellows of Harvard College |
| 18513227 | Methods of Treating Muscular Dystrophy | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17773281 | METHODS AND COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR TARGETING CANCER CELLS | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18267980 | DELIVERY OF ABETA VARIANTS FOR AGGREGATION INHIBITION | Non-Final OA | Baylor College of Medicine |
| 17998233 | CHIMERIC ANTIGEN RECEPTOR FOR TREATMENT OF CANCER | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 17045412 | COMPOSITIONS AND METHODS FOR SOMATIC CELL REPROGRAMMING AND MODULATING IMPRINTING | Final Rejection | Children's Medical Center Corporation |
| 16341508 | UNDIFFERENTIATED STEM CELL-REMOVING AGENT, AND METHOD FOR REMOVING UNDIFFERENTIATED STEM CELLS | Non-Final OA | KEIO UNIVERSITY |
| 18161546 | METHODS OF DIFFERENTIATION TO NEURONAL CELLS AND KITS THEREFOR | Final Rejection | LIFE TECHNOLOGIES CORPORATION |
| 17226642 | Hematopoietic Stem and Progenitor Cell Expansion System | Final Rejection | LIFE TECHNOLOGIES CORPORATION |
| 17756386 | CAR T CELLS WITH ENHANCED METABOLIC FITNESS | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. |
| 18010946 | PLURIPOTENT STEM CELL-DERIVED HEART ORGANOID | Final Rejection | Board of Trustees of Michigan State University |
| 17998183 | FIBROBLAST BASED THERAPY FOR TREATMENT OF PARKINSON'S DISEASE | Non-Final OA | FIGENE, LLC |
| 18488859 | TREATMENT OF CANAVAN DISEASE | Non-Final OA | CITY OF HOPE |
| 18591734 | MIDBRAIN DOPAMINE (DA) NEURONS FOR ENGRAFTMENT | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17771723 | GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | Final Rejection | Iovance Biotherapeutics, Inc. |
| 17833506 | METHOD FOR CULTURING MYOGENIC CELLS, CULTURES OBTAINED THEREFROM, SCREENING METHODS, AND CELL CULTURE MEDIUM | Non-Final OA | Erasmus University Medical Center Rotterdam |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | Final Rejection | CureVac SE |
| 18566898 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TFR1 | Non-Final OA | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
| 18508761 | NUCLEIC ACID CONSTRUCTS ENCODING REPROGRAMMING FACTORS LINKED BY SELF-CLEAVING PEPTIDES | Non-Final OA | Whitehead Institute of Biomedical Research |
| 18504238 | METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS | Final Rejection | Astellas Institute for Regenerative Medicine |
| 18502249 | COMPOSITIONS AND METHODS FOR PRODUCING NON-HUMAN TISSUE ENGINEERED MEAT PRODUCTS | Non-Final OA | MYOS CORP. |
| 17723119 | RNA VIRUS VECTORS CARRYING DAI AND RIPK3 | Final Rejection | Institute For Cancer Research d/b/a The Research Institute Of Fox Chase Cancer Center |
| 18456148 | HUMAN IPSC-BASED DERIVATION OF NK AND T-CELLS USING EARLY NOTCH INDUCTION | Final Rejection | BOSTON MEDICAL CENTER CORPORATION |
| 18361571 | GENE THERAPY VECTORS FOR TREATING HEART DISEASE | Non-Final OA | Tenaya Therapeutics, Inc. |
| 18074272 | DORSALLY-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FROM HUMAN PLURIPOTENT STEM CELLS | Final Rejection | Asterias Biotherapeutics, Inc. |
| 16971242 | INHIBITION OF ZSCAN4 FOR INHIBITION OF TUMOR GROWTH | Final Rejection | University of Maryland, Baltimore |
| 18332823 | METHODS OF INCREASING GROWTH OF CORALS USING A BIOCERAMIC | Non-Final OA | NOVUM CORAL, INC. |
| 17040246 | METHOD FOR REPROGRAMMING SOMATIC CELLS | Non-Final OA | UNIVERSITE CLAUDE BERNARD LYON 1 |
| 18106327 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN INDUCED MESENCHYMAL STEM CELLS | Non-Final OA | SmartCella Solutions AB |
| 18012840 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | Non-Final OA | Lycia Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy